Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SPRB
stocks logo

SPRB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
0.00
-100%
-12.310
-21.84%
--
--
-5.440
-87.27%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Spruce Biosciences, Inc. (SPRB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 822.86%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+8.27%
In Past 3 Month
Stock Price
Go Up
up Image
+822.86%
In Past 3 Month
Wall Street analysts forecast SPRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRB is 209.50 USD with a low forecast of 160.00 USD and a high forecast of 259.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SPRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRB is 209.50 USD with a low forecast of 160.00 USD and a high forecast of 259.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 90.440
sliders
Low
160.00
Averages
209.50
High
259.00
Current: 90.440
sliders
Low
160.00
Averages
209.50
High
259.00
Leerink
Market Perform -> Outperform
upgrade
$160
2025-12-03
New
Reason
Leerink
Price Target
$160
2025-12-03
New
upgrade
Market Perform -> Outperform
Reason
Leerink upgraded Spruce Biosciences to Outperform from Market Perform with a $160 price target.
Leerink
Market Perform -> Outperform
upgrade
$160
2025-12-03
New
Reason
Leerink
Price Target
$160
2025-12-03
New
upgrade
Market Perform -> Outperform
Reason
Leerink upgraded Spruce Biosciences to Outperform from Market Perform with a $160 price target. After receiving Breakthrough Therapy Designation, the shares traded up to almost $200 in October 2025. After conducting a $50M PIPE, the stock has traded down to a more attractive valuation, the firm notes. Leerink is intrigued by the late-stage ERT - tralesinidase alfa - for mucopolysaccharidosis type IIIB, especially with shares trading lower than 1.0-time the firm's peak revenue opportunity.
Citizens JMP
Outperform
maintain
$254 -> $259
2025-11-11
Reason
Citizens JMP
Price Target
$254 -> $259
2025-11-11
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Spruce Biosciences to $259 from $254 and keeps an Outperform rating on the shares. Spruce remains on track to submit its biologics license application for Tralesinidase Alfa Enzyme Replacement Therapy for Sanfilippo Syndrome Type B in 1Q26, the analyst tells investors in a research note. The firm is impressed with management's execution since its acquisition of TA-ERT.
Citizens JMP
Market Perform -> Outperform
upgrade
$254
2025-10-28
Reason
Citizens JMP
Price Target
$254
2025-10-28
upgrade
Market Perform -> Outperform
Reason
Citizens JMP upgraded Spruce Biosciences to Outperform from Market Perform with a $254 price target. The firm cites the company's acquisition of enzyme replacement therapy TA-ERT for Sanfilippo syndrome type B for the upgrade. TA-ERT has five-year data showing the ability to normalize heparin sulfate, the surrogate biomarker for accelerated approval, the analyst tells investors in a research note. Citizens models peak TAE-ERT sales of $170M, which it believes "could be conservative."
Leerink
Market Perform
maintain
$10 -> $160
2025-10-21
Reason
Leerink
Price Target
$10 -> $160
2025-10-21
maintain
Market Perform
Reason
Leerink raised the firm's price target on Spruce Biosciences to $160 from $10 and keeps a Market Perform rating on the shares. Spruce is executing a "significant strategic pivot" by shifting its focus from congenital adrenal hyperplasia to mucopolysaccharidosis type IIIB following a "disappointing update" on its former lead asset, tildacerfont, the analyst noted. The acquisition of tralesinidase alfa enzyme replacement therapy, or TA-ERT, for the pediatric neurodegenerative disorder MPS IIIB "flew under the radar" until the company was granted FDA Breakthrough Therapy Designation for TA-ERT, which is "catapulting the stock higher and allowing the company to secure much needed financing," the analyst added.
RBC Capital
Gregory Renza
Hold
Maintains
$1.5 → $0.5
2025-04-16
Reason
RBC Capital
Gregory Renza
Price Target
$1.5 → $0.5
2025-04-16
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Spruce Biosciences Inc (SPRB.O) is 0.00, compared to its 5-year average forward P/E of -2.19. For a more detailed relative valuation and DCF analysis to assess Spruce Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.19
Current PE
0.00
Overvalued PE
0.54
Undervalued PE
-4.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.76
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.08
Undervalued EV/EBITDA
-3.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
-63.45
Current PS
0.00
Overvalued PS
237.66
Undervalued PS
-364.56
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

SPRB News & Events

Events Timeline

(ET)
2025-12-03
12:30:00
Polyrizon Sees 5,728.31% Surge in Search Activity
select
2025-12-02 (ET)
2025-12-02
13:30:00
Spruce Biosciences Sees 129.55% Surge in Search Activity
select
link
2025-11-10 (ET)
2025-11-10
16:07:26
Spruce Biosciences Announces Q3 EPS of (14.58), Compared to ($15.75) in the Previous Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-02NASDAQ.COM
Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours

  • Biotech Gains in After-Hours Trading: Several biotechnology and pharmaceutical companies saw significant stock price increases in after-hours trading, driven by corporate updates and upcoming events.

  • Jasper Therapeutics' Webinar Announcement: Jasper Therapeutics, Inc. experienced a 21.51% surge after announcing a webinar to discuss findings from the BEACON study and preliminary data from the ETESIAN study.

  • NRx Pharmaceuticals' Presentation at NobleCon21: NRx Pharmaceuticals, Inc. rose 13.39% following the announcement that its CEO will present updates on the company's focus and clinical revenue at an upcoming conference.

  • Protara Therapeutics' Conference Call: Protara Therapeutics, Inc. gained 5.04% after revealing plans for a conference call to discuss interim data from its Phase 2 trial for bladder cancer, with findings to be presented at a major urology meeting.

[object Object]
Preview
9.0
10-09TipRanks
Spruce Biosciences Shares Surge 2,900% Following FDA Breakthrough Therapy Designation Sparks Investor Excitement

  • Dramatic Stock Surge: Spruce Biosciences (SPRB) shares have skyrocketed nearly 2,900% in a week, reaching $234.74, driven by the FDA granting Breakthrough Therapy Designation for its lead drug candidate targeting Sanfilippo Syndrome Type B.

  • Regulatory Momentum and Future Plans: The Breakthrough designation allows for expedited regulatory review, with plans to submit a Biologics License Application by Q1 2026, although analysts remain cautious, rating the stock a Hold with a significant downside price target.

[object Object]
Preview
4.5
10-07TipRanks
Tuesday's Major Stock Market Highlights: Morning News Summary!

  • Stock Market Overview: Investors are looking for key stock market stories, and TipRanks provides a comprehensive list of significant happenings for the day.

  • Resource for Investors: TipRanks serves as a valuable resource for those interested in the latest stock market news and trends.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Spruce Biosciences Inc (SPRB) stock price today?

The current price of SPRB is 90.44 USD — it has increased 0.31 % in the last trading day.

arrow icon

What is Spruce Biosciences Inc (SPRB)'s business?

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.

arrow icon

What is the price predicton of SPRB Stock?

Wall Street analysts forecast SPRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRB is 209.50 USD with a low forecast of 160.00 USD and a high forecast of 259.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Spruce Biosciences Inc (SPRB)'s revenue for the last quarter?

Spruce Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Spruce Biosciences Inc (SPRB)'s earnings per share (EPS) for the last quarter?

Spruce Biosciences Inc. EPS for the last quarter amounts to -14.58 USD, decreased -7.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for Spruce Biosciences Inc (SPRB)'s fundamentals?

The market is revising No Change the revenue expectations for Spruce Biosciences, Inc. (SPRB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 822.86%.
arrow icon

How many employees does Spruce Biosciences Inc (SPRB). have?

Spruce Biosciences Inc (SPRB) has 21 emplpoyees as of December 05 2025.

arrow icon

What is Spruce Biosciences Inc (SPRB) market cap?

Today SPRB has the market capitalization of 96.50M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free